Improving Health Through Pioneering Non-Invasive Technologies
Failure to detect diseases early-on has a significant impact on visual outcomes, health care costs, and quality of life.
What if we could intervene sooner?
The eye is a unique window into a person’s health. Zilia’s technology harnesses the power of light to assess biomarkers associated with ocular, neurological, and systemic conditions. It holds the potential to empower scientists and health care professionals with new key clinical information.
How Does it Work?
01. Patient Assessment
- Light emitted from the device travels through the eye and reflects on the eye fundus.
02. Spectral Analysis
- The light signal that returns is analyzed to provide a series of images and high-quality spectra.
03. Deep Insights
- Data is processed in real-time and actionable biomarker data is presented in a user-friendly interface.
What is Spectrometry?
A portion of the light reflected from the eye fundus is used for imaging while the other portion, coming from a targeted location, provides reflectance spectra, which act as fingerprints of the tissue of interest. These spectra are then deconvoluted for the quantification of relevant biomarkers.
Generating Value in Health Care
Too often, ocular diseases are diagnosed late because existing tools have low sensitivity or assess damages already made to the eye. By quantifying key biomarkers, eye care professionals will have access to unprecedented understanding, leading to earlier diagnosis and treatment.
Enabling researchers to effectively measure biomarkers in the eye opens the way for new therapies, helps identify at-risk populations, and improves the management of various diseases.
Data-driven technologies are major contributors to advances in drug discovery. With its non-invasive technological platform, Zilia provides unprecedented data, enabling pharmaceutical companies to direct their resources appropriately and cost-effectively to create and validate more efficient drugs faster.